Recommendation
- https://www.dovepress.com/a-review-of-randomized-controlled-trials-of-hereditary-angioedema-long-peer-reviewed-fulltext-article-JAALong term prophylaxis for HAE with C1 inhibitor | JAAMar 9, 2023 ... C1-INH replacement therapy is a first-line intervention for on-demand (acute) treatment of HAE attacks, short-term prophylaxis before high-risk procedures, and ...
- https://www.annallergy.org/article/S1081-1206(20)30333-1/fulltextAnnals of Allergy, Asthma & ImmunologyLong-term safety and efficacy of subcutaneous C1-inhibitor in older ...May 19, 2020 ... ∙ Kashkin, J. Update on the use of C1-esterase inhibitor replacement therapy in the acute and prophylactic treatment of hereditary angioedema.
- https://www.nejm.org/doi/full/10.1056/NEJMoa1613627Prevention of Hereditary Angioedema Attacks with a Subcutaneous ...Mar 23, 2017 ... This treatment effect was associated with an overall reduced need for rescue medication. C1 inhibitor replacement for prophylaxis is currently ...
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7328861/Advances in Hereditary Angioedema: The Prevention of ...Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy
- https://link.springer.com/article/10.1007/s40629-018-0088-5Guideline: Hereditary angioedema due to C1 inhibitor deficiency ...Jan 17, 2019 ... Treatment of laryngeal edema in the setting of HAE-C1-INH depends on how advanced laryngeal edema is. In the case of life-threatening ...
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10010185/PubMed Central (PMC)A Review of Randomized Controlled Trials of Hereditary ...Mar 9, 2023 ... C1-INH replacement therapy is a first-line intervention for on-demand (acute) treatment of HAE attacks, short-term prophylaxis before high-risk procedures, and ...
- https://www.sciencedirect.com/science/article/pii/S2213219818300333Health-Related Quality of Life with Subcutaneous C1-Inhibitor for ...... C1-Inhibitor Replacement Therapy). Ninety patients with C1-INH-HAE were randomized to 1 of 4 treatment sequences: C1-INH(SC) 40 or 60 IU/kg twice weekly for ...
- https://primaryimmune.org/understanding-primary-immunodeficiency/types-of-pi/complement-deficienciesComplement deficiencies | Immune Deficiency FoundationAcute treatments for HAE include C1 inhibitor, a replacement therapy [both plasma-derived (concentrate) and recombinant products are available]; ecallantide ...
- https://newsroom.csl.com/2012-05-03-CSL-Behring-Initiates-Study-of-Subcutaneous-Administration-of-C1-esterase-inhibitor-in-Patients-with-Hereditary-AngioedemaGlobal Newsroom | CSLCSL Behring Initiates Study of Subcutaneous Administration of C1 ...May 3, 2012 ... Part of the COMPACT (Clinical Studies for Optimal Management in Preventing Angioedema with Low-Volume Subcutaneous C1-inhibitor Replacement ...
- https://www.grandviewresearch.com/industry-analysis/plasma-protease-c1-inhibitor-market-reportPlasma Protease C1-inhibitor Market Size Report, 2030The region has a high prevalence of hereditary angioedema (HAE), necessitating effective treatment options like C1-inhibitors. Its advanced healthcare ...
Recommend
All Categories
Others
Privacy Policy
Terms of Use
Welcome to kkinews.com, we strive to provide you with the latest news,
hot topics and in-depth articles.
Whether it's real-time news or in-depth analysis from multiple angles,
you can easily get it here. kkinews.com aims to provide users with a
convenient and comprehensive information acquisition experience to
help you always stay at the forefront of information.
Copyright © 2025 Kkinews. All rights reserved